210 related articles for article (PubMed ID: 30884797)
1. Introduction of Nonacidic Side Chains on 6-Ethylcholane Scaffolds in the Identification of Potent Bile Acid Receptor Agonists with Improved Pharmacokinetic Properties.
Finamore C; Baronissi G; Marchianò S; Di Leva FS; Carino A; Monti MC; Limongelli V; Zampella A; Fiorucci S; Sepe V
Molecules; 2019 Mar; 24(6):. PubMed ID: 30884797
[TBL] [Abstract][Full Text] [Related]
2. Navigation in bile acid chemical space: discovery of novel FXR and GPBAR1 ligands.
Finamore C; Festa C; Renga B; Sepe V; Carino A; Masullo D; Biagioli M; Marchianò S; Capolupo A; Monti MC; Fiorucci S; Zampella A
Sci Rep; 2016 Jul; 6():29320. PubMed ID: 27381677
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological evaluation of potent dual agonists of nuclear and membrane bile acid receptors.
D'Amore C; Di Leva FS; Sepe V; Renga B; Del Gaudio C; D'Auria MV; Zampella A; Fiorucci S; Limongelli V
J Med Chem; 2014 Feb; 57(3):937-54. PubMed ID: 24387325
[TBL] [Abstract][Full Text] [Related]
4. Investigation on bile acid receptor regulators. Discovery of cholanoic acid derivatives with dual G-protein coupled bile acid receptor 1 (GPBAR1) antagonistic and farnesoid X receptor (FXR) modulatory activity.
Sepe V; Renga B; Festa C; Finamore C; Masullo D; Carino A; Cipriani S; Distrutti E; Fiorucci S; Zampella A
Steroids; 2016 Jan; 105():59-67. PubMed ID: 26607331
[TBL] [Abstract][Full Text] [Related]
5. Exploitation of cholane scaffold for the discovery of potent and selective farnesoid X receptor (FXR) and G-protein coupled bile acid receptor 1 (GP-BAR1) ligands.
Festa C; Renga B; D'Amore C; Sepe V; Finamore C; De Marino S; Carino A; Cipriani S; Monti MC; Zampella A; Fiorucci S
J Med Chem; 2014 Oct; 57(20):8477-95. PubMed ID: 25247751
[TBL] [Abstract][Full Text] [Related]
6. Insights on FXR selective modulation. Speculation on bile acid chemical space in the discovery of potent and selective agonists.
Sepe V; Festa C; Renga B; Carino A; Cipriani S; Finamore C; Masullo D; Del Gaudio F; Monti MC; Fiorucci S; Zampella A
Sci Rep; 2016 Jan; 6():19008. PubMed ID: 26740187
[TBL] [Abstract][Full Text] [Related]
7. Nonacidic Farnesoid X Receptor Modulators.
Flesch D; Cheung SY; Schmidt J; Gabler M; Heitel P; Kramer J; Kaiser A; Hartmann M; Lindner M; Lüddens-Dämgen K; Heering J; Lamers C; Lüddens H; Wurglics M; Proschak E; Schubert-Zsilavecz M; Merk D
J Med Chem; 2017 Aug; 60(16):7199-7205. PubMed ID: 28749691
[TBL] [Abstract][Full Text] [Related]
8. Steroidal scaffolds as FXR and GPBAR1 ligands: from chemistry to therapeutical application.
Sepe V; Distrutti E; Limongelli V; Fiorucci S; Zampella A
Future Med Chem; 2015; 7(9):1109-35. PubMed ID: 26132522
[TBL] [Abstract][Full Text] [Related]
9. Chemistry and Pharmacology of GPBAR1 and FXR Selective Agonists, Dual Agonists, and Antagonists.
De Marino S; Festa C; Sepe V; Zampella A
Handb Exp Pharmacol; 2019; 256():137-165. PubMed ID: 31201554
[TBL] [Abstract][Full Text] [Related]
10. Structure-guided modification of isoxazole-type FXR agonists: Identification of a potent and orally bioavailable FXR modulator.
Luo G; Lin X; Li Z; Xiao M; Li X; Zhang D; Xiang H
Eur J Med Chem; 2021 Jan; 209():112910. PubMed ID: 33049605
[TBL] [Abstract][Full Text] [Related]
11. Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH).
Fiorucci S; Biagioli M; Sepe V; Zampella A; Distrutti E
Expert Opin Investig Drugs; 2020 Jun; 29(6):623-632. PubMed ID: 32552182
[TBL] [Abstract][Full Text] [Related]
12. Development of bile acid activated receptors hybrid molecules for the treatment of inflammatory and metabolic disorders.
Fiorucci S; Sepe V; Biagioli M; Fiorillo B; Rapacciuolo P; Distrutti E; Zampella A
Biochem Pharmacol; 2023 Oct; 216():115776. PubMed ID: 37659739
[TBL] [Abstract][Full Text] [Related]
13. Bile acid-activated receptors and the regulation of macrophages function in metabolic disorders.
Fiorucci S; Baldoni M; Ricci P; Zampella A; Distrutti E; Biagioli M
Curr Opin Pharmacol; 2020 Aug; 53():45-54. PubMed ID: 32480317
[TBL] [Abstract][Full Text] [Related]
14. Structural Insight into the Binding Mode of FXR and GPBAR1 Modulators.
Di Leva FS; Di Marino D; Limongelli V
Handb Exp Pharmacol; 2019; 256():111-136. PubMed ID: 31161298
[TBL] [Abstract][Full Text] [Related]
15. Farnesoid X receptor: from medicinal chemistry to clinical applications.
Fiorucci S; Mencarelli A; Distrutti E; Zampella A
Future Med Chem; 2012 May; 4(7):877-91. PubMed ID: 22571613
[TBL] [Abstract][Full Text] [Related]
16. Bile acid receptors and the kidney.
Herman-Edelstein M; Weinstein T; Levi M
Curr Opin Nephrol Hypertens; 2018 Jan; 27(1):56-62. PubMed ID: 29045336
[TBL] [Abstract][Full Text] [Related]
17. Bile acid receptors in non-alcoholic fatty liver disease.
Li Y; Jadhav K; Zhang Y
Biochem Pharmacol; 2013 Dec; 86(11):1517-24. PubMed ID: 23988487
[TBL] [Abstract][Full Text] [Related]
18. Progress and challenges of selective Farnesoid X Receptor modulation.
Massafra V; Pellicciari R; Gioiello A; van Mil SWC
Pharmacol Ther; 2018 Nov; 191():162-177. PubMed ID: 29933033
[TBL] [Abstract][Full Text] [Related]
19. Recent Progress on Bile Acid Receptor Modulators for Treatment of Metabolic Diseases.
Xu Y
J Med Chem; 2016 Jul; 59(14):6553-79. PubMed ID: 26878262
[TBL] [Abstract][Full Text] [Related]
20. Reversal of metabolic disorders by pharmacological activation of bile acid receptors TGR5 and FXR.
Jadhav K; Xu Y; Xu Y; Li Y; Xu J; Zhu Y; Adorini L; Lee YK; Kasumov T; Yin L; Zhang Y
Mol Metab; 2018 Mar; 9():131-140. PubMed ID: 29361497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
